As the hubbub around ASCO 2018 comes to an end, what are the main takeaways?

For sure, the media blitz distorts the importance of some presentations versus others. In most cases, study results are preliminary, with further follow-up and traditional peer reviews still pending.

With these caveats, one presentation (Abstract #8000), A.R.R.O.W (A randomized open-label study with Relapsed and refractory myeloma Receiving carfilzomib in combination with dexamethasone comparing Once Weekly versus twice weekly carfilzomib), is exceptional in that not only do results demonstrate value for the convenient once-weekly schedule, but the results have been simultaneously published with peer-review in The Lancet. The safe, once-weekly carfilzomib schedule produced longer remissions (PFS 11.2 months versus 7.6 months).

A sobering cautionary abstract was from the FDA (Abstract #8008) summarizing results from the checkpoint inhibitor, pembrolizumab, trials KEYNOTE-183 (pembrolizumab/pomalidomide/dexamethasone) (Abstract #8021) and KEYNOTE-185 (pembrolizumab/lenalidomide/dex) (Abstract #8010). Very encouraging results had been presented in the past, but ultimately dangerous immune toxicities emerged, prompting the FDA to halt the trials and review the data. Clearly, caution with early results is important.

Results with the bb2121 CAR-T trial were again presented in Abstracts #8007 and #8024. Key points were the median remission duration (PFS 11.8 months) and high level of some degree of MRD negativity, although only 2 patients out of 9 were at the 10-6 sensitivity level. So, continued encouraging results with more to follow.

For other myeloma studies, there were really no surprises. The combination of pomalidomide Vd showed superiority over Vd in patients refractory to lenalidomide (Revlimid®), which is very encouraging for patients (Abstract #8001). The combination of the new agent venetoclax with carfilzomib (Kyprolis®) showed a high response rate (88% overall) in both high- and low-risk patients (Abstract #8004).  It was also good to see that the combination of daratumumab with carfilzomib was very safe and was effective in lenalidomide-refractory patients, with a median remission duration (PFS) of 14 months  (Abstract #8002).

Thus, through the media blitz, there are important messages for patients! We are privileged to have a series of videos from top opinion leaders who emphasize in their own words the significance of these presentations I have mentioned. Each meeting gives us small steps forward to improve outcomes for myeloma patients.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.